Mark W. Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark W. Russo has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Lon Eskind
Division of Hepatology and Transplant Surgery, Carolinas Healthcare System, Charlotte, NC
4 shared publicationsHerbert L. Bonkovsky
Wake Forest University School of Medicine, Winston-Salem, NC, USA
3 shared publicationsPaul A. Schmeltzer
Carolinas Medical Center
3 shared publicationsRobert J. Fontana
University of Michigan School of Medicine, Ann Arbor, MI, USA
3 shared publicationsDavid M. Levi
Divisions of Transplant Surgery, Carolinas HealthCare System, Charlotte, NC
2 shared publicationsJay H. Hoofnagle
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
2 shared publications
Latest Publications
- 19 December 2018
- Published by Springer Nature
- p. 165-177
General Care of the Cirrhotic Patient
- 8 November 2018
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 24 (11) , 1561-1569
Strategies That Reduce 90‐Day Readmissions and Inpatient Costs After Liver Transplantation
Liver transplantation (LT) is hospital‐resource intensive and associated with high rates of readmission. We have previously shown a reduction in 30‐day readmission rates by implementing a specifically designed protocol to increase access to outpatient care. The aim of this work is to determine if the strategies that reduce 30‐day readmission after LT were effective in also reducing 90‐day readmission rates and costs. A protocol was developed to reduce inpatient readmissions after LT that expanded outpatient services and provided alternatives to readmission. The 90‐day readmission rates and costs were compared before and after implementing strategies outlined in the protocol. Multivariable analysis was used to control for potential confounding factors. Over the study period, 304 adult primary LTs were performed on patients with a median biological Model for End‐Stage Liver Disease of 22. There were 112 (37%) patients who were readmitted within 90 days of transplant. The readmission rates before and after implementation of the protocol were 53% and 26%, respectively ( P < 0.001). The most common reason for readmission was elevated liver tests/rejection (24%). In multivariable analysis, the protocol remained associated with avoiding readmission (odds ratio, 0.33; 95% confidence interval, 0.20‐0.55; P < 0.001). The median length of stay after transplant before and after protocol implementation was 8 days and 7 days, respectively. A greater proportion of patients were discharged to hospital lodging after protocol implementation (10% versus 19%; P = 0.03). The 90‐day readmission costs were reduced by 55%, but the total 90‐day costs were reduced by only 2.7% because of higher outpatient costs and index admission costs. In conclusion, 90‐day readmission rates and readmission costs can be reduced by improving access to outpatient services and hospital‐local lodging. Total 90‐day costs were similar between the 2 groups because of higher outpatient costs after the protocol was introduced.
- 8 November 2018
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 24 (11) , 1561-1569
Strategies That Reduce 90‐Day Readmissions and Inpatient Costs After Liver Transplantation
Liver transplantation (LT) is hospital‐resource intensive and associated with high rates of readmission. We have previously shown a reduction in 30‐day readmission rates by implementing a specifically designed protocol to increase access to outpatient care. The aim of this work is to determine if the strategies that reduce 30‐day readmission after LT were effective in also reducing 90‐day readmission rates and costs. A protocol was developed to reduce inpatient readmissions after LT that expanded outpatient services and provided alternatives to readmission. The 90‐day readmission rates and costs were compared before and after implementing strategies outlined in the protocol. Multivariable analysis was used to control for potential confounding factors. Over the study period, 304 adult primary LTs were performed on patients with a median biological Model for End‐Stage Liver Disease of 22. There were 112 (37%) patients who were readmitted within 90 days of transplant. The readmission rates before and after implementation of the protocol were 53% and 26%, respectively ( P < 0.001). The most common reason for readmission was elevated liver tests/rejection (24%). In multivariable analysis, the protocol remained associated with avoiding readmission (odds ratio, 0.33; 95% confidence interval, 0.20‐0.55; P < 0.001). The median length of stay after transplant before and after protocol implementation was 8 days and 7 days, respectively. A greater proportion of patients were discharged to hospital lodging after protocol implementation (10% versus 19%; P = 0.03). The 90‐day readmission costs were reduced by 55%, but the total 90‐day costs were reduced by only 2.7% because of higher outpatient costs and index admission costs. In conclusion, 90‐day readmission rates and readmission costs can be reduced by improving access to outpatient services and hospital‐local lodging. Total 90‐day costs were similar between the 2 groups because of higher outpatient costs after the protocol was introduced.
- 28 December 2017
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 12 (3) , 265-275
Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma
Introduction: Unresectable hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). The Milan criteria became standard criteria but expansion beyond the Milan criteria (tumor size and number) have resulted in similar post-transplant outcomes, thus suggesting LT is a viable treatment option for HCC presenting beyond the Milan criteria Areas covered: Expanded criteria and the use of downstaging therapies to meet Milan criteria are reviewed. Surrogates of tumor biology (including biomarkers and response to therapy) are described in detail. The controversy regarding treatment of HCV infection prior to transplant for HCC is addressed. Predictors of post-transplant recurrence and therapeutic options are explored. English-language manuscripts pertaining to LT criteria for HCC, downstaging, and tumor prognosis were reviewed. Effort was made to include manuscripts from throughout the world to ensure the reader a broad international perspective. Expert commentary: Patients can be successfully transplanted with HCC beyond Milan criteria, or patients beyond Milan criteria can be downstaged to within Milan criteria and achieve successful post-liver transplant outcomes. The current reliance on tumor burden (size and number) alone ignores the mounting data supporting the prognostic use of additional surrogates of tumor biology in identifying appropriate candidates.
- 28 December 2017
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 12 (3) , 265-275
Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma
Introduction: Unresectable hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). The Milan criteria became standard criteria but expansion beyond the Milan criteria (tumor size and number) have resulted in similar post-transplant outcomes, thus suggesting LT is a viable treatment option for HCC presenting beyond the Milan criteria Areas covered: Expanded criteria and the use of downstaging therapies to meet Milan criteria are reviewed. Surrogates of tumor biology (including biomarkers and response to therapy) are described in detail. The controversy regarding treatment of HCV infection prior to transplant for HCC is addressed. Predictors of post-transplant recurrence and therapeutic options are explored. English-language manuscripts pertaining to LT criteria for HCC, downstaging, and tumor prognosis were reviewed. Effort was made to include manuscripts from throughout the world to ensure the reader a broad international perspective. Expert commentary: Patients can be successfully transplanted with HCC beyond Milan criteria, or patients beyond Milan criteria can be downstaged to within Milan criteria and achieve successful post-liver transplant outcomes. The current reliance on tumor burden (size and number) alone ignores the mounting data supporting the prognostic use of additional surrogates of tumor biology in identifying appropriate candidates.
- Open Access
- 29 September 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 10 (3) , 75-78
Impact of hepatitis C virus eradication on hepatocellular carcinoma rates
- 29 September 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 10 (3) , 75-78
Open AccessImpact of hepatitis C virus eradication on hepatocellular carcinoma rates
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1124
A Protocol that Reduces 30 and 90 Day Readmissions and Costs After Liver Transplantation
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1124
A Protocol that Reduces 30 and 90 Day Readmissions and Costs After Liver Transplantation
- 12 November 2016
- Published by Wiley in Liver International
- Vol. 37 (5) , 757-764
Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance
Background & Aims: Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality.Methods: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non‐survivors.Results: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs‐122, ‐4463 and ‐4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA‐122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR‐122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively.Conclusions: Serum miRNA‐122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA‐122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
- 12 November 2016
- Published by Wiley in Liver International
- Vol. 37 (5) , 757-764
Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance
Background & Aims: Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality.Methods: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non‐survivors.Results: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs‐122, ‐4463 and ‐4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA‐122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR‐122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively.Conclusions: Serum miRNA‐122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA‐122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
- Open Access
- 15 September 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (1) , 336-340
Workforce in hepatology
The field of hepatology has experienced dramatic changes since the last workforce study in hepatology over 15 years ago. Hepatology practice has been dominated by hepatitis C but is now being overtaken by patients with nonalcoholic fatty liver disease. Expertise once attainable only through informal training, hepatology now has an accredited fellowship pathway and is recognized as a distinct discipline from gastroenterology with its own board certification. These changes that have occurred since the last workforce study in the prevalence and therapy of liver diseases and training may impact workforce needs. The time has come to conduct an updated analysis of the state of the hepatology workforce. The purpose of this article is to discuss the current issues facing training and workforce in hepatology and propose the next steps in conducting a workforce study. (Hepatology 2017;65:336‐340).
- 15 September 2016
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (1) , 336-340
Open AccessWorkforce in hepatology
The field of hepatology has experienced dramatic changes since the last workforce study in hepatology over 15 years ago. Hepatology practice has been dominated by hepatitis C but is now being overtaken by patients with nonalcoholic fatty liver disease. Expertise once attainable only through informal training, hepatology now has an accredited fellowship pathway and is recognized as a distinct discipline from gastroenterology with its own board certification. These changes that have occurred since the last workforce study in the prevalence and therapy of liver diseases and training may impact workforce needs. The time has come to conduct an updated analysis of the state of the hepatology workforce. The purpose of this article is to discuss the current issues facing training and workforce in hepatology and propose the next steps in conducting a workforce study. (Hepatology 2017;65:336‐340).
- 26 May 2016
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (6) , 765-772
A prospective study of a protocol that reduces readmission after liver transplantation
Health care has shifted to placing priority on quality and value instead of volume. Liver transplantation uses substantial resources and is associated with high readmission rates. Our goal was to determine if a protocol designed to reduce readmission after liver transplant was effective. We conducted a prospective study of a protocol designed to reduce readmission rates after liver transplantation by expanding outpatient services and alternatives to readmission. The 30‐day readmission rate 1 year after implementing the protocol was compared to the 30‐day rate for 2 years prior to implementation. Multivariate analysis was used to control for potential confounding factors. Over the study period, 167 adult primary liver transplants were performed with a mean biological Model for End‐Stage Liver Disease score of 21 ± 8. Fifty‐seven (34%) patients were readmitted. The most common reason for readmission was biliary complications (n = 13). The 30‐day readmission rate decreased from 40% before implementing the protocol to 20% after implementation (P = 0.02). In multivariate analysis, the protocol remained associated with readmission (odds ratio, 0.39; 95% confidence interval, 0.16‐0.92; P = 0.03). The mean length of stay after transplant was 13 ± 12 days preprotocol and 9 ± 5 days postprotocol (P = 0.09). Alternatives to readmission, including hospital lodging and observation status, were main factors in reducing readmission rates. If the most recent definitions of inpatient admission and observation status were applied over the entire study period, then the readmission rates preprotocol and postprotocol were 31% and 20% indicating that the revised definition of observation status accounted for 45% of the reduction in the readmission rate. Readmission after liver transplantation can be reduced without increasing length of stay by implementing a specifically designed protocol that expands outpatient services and alternatives to inpatient admission. Liver Transplantation 22 765–772 2016 AASLD.
- 26 May 2016
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (6) , 765-772
A prospective study of a protocol that reduces readmission after liver transplantation
Health care has shifted to placing priority on quality and value instead of volume. Liver transplantation uses substantial resources and is associated with high readmission rates. Our goal was to determine if a protocol designed to reduce readmission after liver transplant was effective. We conducted a prospective study of a protocol designed to reduce readmission rates after liver transplantation by expanding outpatient services and alternatives to readmission. The 30‐day readmission rate 1 year after implementing the protocol was compared to the 30‐day rate for 2 years prior to implementation. Multivariate analysis was used to control for potential confounding factors. Over the study period, 167 adult primary liver transplants were performed with a mean biological Model for End‐Stage Liver Disease score of 21 ± 8. Fifty‐seven (34%) patients were readmitted. The most common reason for readmission was biliary complications (n = 13). The 30‐day readmission rate decreased from 40% before implementing the protocol to 20% after implementation (P = 0.02). In multivariate analysis, the protocol remained associated with readmission (odds ratio, 0.39; 95% confidence interval, 0.16‐0.92; P = 0.03). The mean length of stay after transplant was 13 ± 12 days preprotocol and 9 ± 5 days postprotocol (P = 0.09). Alternatives to readmission, including hospital lodging and observation status, were main factors in reducing readmission rates. If the most recent definitions of inpatient admission and observation status were applied over the entire study period, then the readmission rates preprotocol and postprotocol were 31% and 20% indicating that the revised definition of observation status accounted for 45% of the reduction in the readmission rate. Readmission after liver transplantation can be reduced without increasing length of stay by implementing a specifically designed protocol that expands outpatient services and alternatives to inpatient admission. Liver Transplantation 22 765–772 2016 AASLD.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1059
Sa1532 Tenascin-C: A Novel Plasma Biomarker in Hepatitis C-Mediated Liver Disease
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1059
Sa1532 Tenascin-C: A Novel Plasma Biomarker in Hepatitis C-Mediated Liver Disease
- 25 November 2015
- Published by Wiley in Liver International
- Vol. 36 (4) , 603-609
Liver injury from nonsteroidal anti‐inflammatory drugs in the United States
Background & Aims: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are commonly used and have been associated with hepatotoxicity. Studies of liver injury from NSAIDs have been retrospective and prospective data are lacking. The aim was to report the features and outcomes of the subjects with severe drug‐induced liver injury from NSAIDS.Methods: The U.S. Drug Induced Liver Injury Network is a prospective registry of idiosyncratic drug hepatotoxicity. All patients are evaluated in a standard fashion and followed up for at least 6 months.Results: Of 1221 Drug Induced Liver Injury Network cases that were adjudicated, 30 cases were attributed to eight different NSAIDs. The mean age was 52 years old, 24 (80%) were women, and 21 (70%) were Caucasian. The mean latency was 67 days. Common signs and symptoms at presentation were nausea (73%), jaundice (67%) and dark urine (67%). Mean peak serum aspartate aminotransferase, alanine aminotransferase, total bilirubin and alkaline phosphatase were 898 U/L, 1060 U/L, 12.2 mg/dl and 326 U/L. The most common pattern of injury was hepatocellular (70%) and autoantibodies were detected in 33% of cases. Diclofenac, was the most frequently implicated NSAID (16/30 cases), and characterized by hepatocellular injury. Seventeen cases resulted in hospitalization or prolongation of hospitalization and one patient died from complications of Stevens–Johnson syndrome because of diclofenac.Conclusions: Hepatocellular injury is the most common pattern seen with NSAID hepatotoxicity, and diclofenac is the most frequently implicated agent. Given the number of NSAID alternatives, diclofenac should be reserved for patients who fail other NSAIDs and a high level of suspicion for hepatotoxicity should be maintained.
- 25 November 2015
- Published by Wiley in Liver International
- Vol. 36 (4) , 603-609
Liver injury from nonsteroidal anti‐inflammatory drugs in the United States
Background & Aims: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are commonly used and have been associated with hepatotoxicity. Studies of liver injury from NSAIDs have been retrospective and prospective data are lacking. The aim was to report the features and outcomes of the subjects with severe drug‐induced liver injury from NSAIDS.Methods: The U.S. Drug Induced Liver Injury Network is a prospective registry of idiosyncratic drug hepatotoxicity. All patients are evaluated in a standard fashion and followed up for at least 6 months.Results: Of 1221 Drug Induced Liver Injury Network cases that were adjudicated, 30 cases were attributed to eight different NSAIDs. The mean age was 52 years old, 24 (80%) were women, and 21 (70%) were Caucasian. The mean latency was 67 days. Common signs and symptoms at presentation were nausea (73%), jaundice (67%) and dark urine (67%). Mean peak serum aspartate aminotransferase, alanine aminotransferase, total bilirubin and alkaline phosphatase were 898 U/L, 1060 U/L, 12.2 mg/dl and 326 U/L. The most common pattern of injury was hepatocellular (70%) and autoantibodies were detected in 33% of cases. Diclofenac, was the most frequently implicated NSAID (16/30 cases), and characterized by hepatocellular injury. Seventeen cases resulted in hospitalization or prolongation of hospitalization and one patient died from complications of Stevens–Johnson syndrome because of diclofenac.Conclusions: Hepatocellular injury is the most common pattern seen with NSAID hepatotoxicity, and diclofenac is the most frequently implicated agent. Given the number of NSAID alternatives, diclofenac should be reserved for patients who fail other NSAIDs and a high level of suspicion for hepatotoxicity should be maintained.